cancer treatment

The Rise of Dual Payload ADCs/PDCs: A Comprehensive Overview of Research and Development

by
The Rise of Dual Payload ADCs/PDCs: A Comprehensive Overview of Research and Development

Introduction The emergence of dual payload antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs) marks a significant evolution in the field of targeted therapy. 01 Background Antibody-drug conjugates (ADCs) have garnered attention for their ability to deliver cytotoxic agents precisely to cancer cells, earning them the title of “magic bullets” for tumor treatment.However, ADCs still face … Read more

Sutro R&D Day: Next Generation ADC

by
Sutro R&D Day: Next Generation ADC

On November 12, Sutro held its R&D Day event. With the complete termination of the original pillar product FRα, Sutro’s situation is not optimistic. The focus of this R&D Day event remains on ADCs.Related Reading: Sutro 25H1: ROR1 is returned, continuing to push the dual payload platformSutro pointed out that its platform expands the therapeutic … Read more

Comprehensive Analysis of ADC Conjugation Technology

by
Comprehensive Analysis of ADC Conjugation Technology

Abstract: Antibody-drug conjugates (ADCs), known as “precision missiles” for cancer treatment, can accurately target tumor cells without harming normal tissues. The core of this technology lies inconjugation technology— the method of linking cytotoxic drugs (the warhead) with antibodies (the navigation system). This article starts from the working principle of ADCs, breaking down three major categories … Read more

How Do Antibody-Drug Conjugates (ADCs) Accurately Hit Their Targets? In-Depth Analysis of the Latest Analytical Techniques and Core Pharmacokinetic Modeling Strategies

by

On the battlefield of precise cancer treatment, Antibody-Drug Conjugates (ADCs) act like a “biological missile,” leveraging their precise targeting capabilities and powerful lethality to become a cornerstone of tumor therapy. However, the journey of this “missile” within the body is exceptionally complex, and accurately tracking it and predicting its behavior has become the key to … Read more

ADC Drugs: Decoding the Present and Future of Precision Cancer ‘Missiles’

by
ADC Drugs: Decoding the Present and Future of Precision Cancer 'Missiles'

When the dual-antibody ADC drug iza-bren presented an astonishing “objective response rate of 100%” at the 2025 World Lung Cancer Conference, this category of drugs, known as “biological missiles,” completely rewrote the narrative logic of tumor treatment. From the first approved drug, trastuzumab, to the domestically developed dual-antibody ADCs, ADC drugs have established a foothold … Read more

Unveiling the Potential of Antibody-Drug Conjugates

by
Unveiling the Potential of Antibody-Drug Conjugates

This article, “Unveiling the Potential of Antibody-Drug Conjugates,” is an excellent industry review that provides a panoramic view of the hot field of Antibody-Drug Conjugates (ADCs). Next, we will journey from history to the future, delving into molecular mechanisms and clinical practices, connecting textbook knowledge to cutting-edge research. A Precision Guided “Trojan Horse”: An In-Depth … Read more

Latest Trends in Antibody Drugs for 2024: Which Will Lead the Next Decade – Bispecific Antibodies, ADCs, or PROTACs?

by
Latest Trends in Antibody Drugs for 2024: Which Will Lead the Next Decade - Bispecific Antibodies, ADCs, or PROTACs?

In 2024, the global antibody drug market is expected to experience explosive growth. According to IQVIA, global spending on biopharmaceuticals is projected to exceed $892 billion by 2028, with antibody drugs holding a significant share. In the fields of oncology and autoimmune diseases, three major technological routes—bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and proteolysis-targeting chimeras … Read more

Key Considerations in ADC Design Based on Pharmacokinetics

by
Key Considerations in ADC Design Based on Pharmacokinetics

Please click the “Bio New Thinking” above to follow for more exciting content! Introduction With the continuous improvement of biopharmaceutical research and clinical research levels, the research and application of Antibody-Drug Conjugates (ADCs) have been increasing. ADCs are mainly composed of antibodies, linkers, and small molecule toxins, combining high targeting specificity with high cytotoxicity. However, … Read more

16 ADC Drugs Approved Worldwide: Everything You Need to Know

by
16 ADC Drugs Approved Worldwide: Everything You Need to Know

In the early 20th century, Paul Ehrlich first proposed the famous “magic bullet” theory, suggesting that it is possible to find and develop drugs that specifically target the unique structural features of pathogens, killing only the pathogens without affecting normal tissues and cells. Subsequently, the concept of antibody-drug conjugates (ADCs) was introduced, combining the target … Read more

Complement and Disease: Misdiagnosis Strategies for Atypical Hemolytic Uremic Syndrome

by
Complement and Disease: Misdiagnosis Strategies for Atypical Hemolytic Uremic Syndrome

Atypical hemolytic uremic syndrome (aHUS) is a type of complement-mediated thrombotic microangiopathy (TMA), characterized by microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and multi-organ damage as typical manifestations, with infection and pregnancy being the main triggers.[1] The condition of aHUS is usually quite critical. In the pre-complement treatment era, the mortality rate during the acute phase was … Read more